The prevalence and disease conditions of mesalazine intolerance in inflammatory bowel disease: Multicenter retrospective observational study

The prevalence and disease conditions of mesalazine intolerance in inflammatory bowel disease: Multicenter retrospective observational study - The investigation for mesalazine intolerance in patients with inflammatory bowel disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029338

Enrollment

1000

Registered

2018-11-11

Start date

2017-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel diseasa

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Outpatients and inpatients (UC or CD, IBD-unclassified and intestinal Behcet's disease) at Okayama University hospital and the research institutions betwee January 2016 and December 2016 2.Patients with the past or current history of mesalazine therapy 3.Patients whose disease courses after mesalazine administration can be examined through in the medical records

Exclusion criteria

Exclusion criteria: Patients who refused the participation in this study due to the published information

Design outcomes

Primary

Measure	Time frame
The incidence rate of mesalazine intolerance in IBD patients according to the time of disease onset	—

Countries

Japan

Contacts

Public ContactSakiko Hiraoka

Okayama University Graduate School of Medicine Department of Gastroenterology and Hepatology

sakikoh@cc.okayama-.u.ac.jp086-235-7219

Outcome results